Compare Crispr Therapeutics AG (CRSP) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lowe`s Companies Inc — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while Lowe`s Companies Inc trades at $207.21 (market cap $116.45B). The key difference: Lowe`s Companies Inc is far larger — about 23.4× Crispr Therapeutics AG's market cap, and Lowe`s Companies Inc pays a 2.41% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LOW | |
|---|---|---|
Market Cap | $4.97B | $116.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $287.39 |
52-Week Low | $44.34 | $206.62 |
Enterprise Value | $3.32B | $158.20B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Lowe's (LOW) trades at $207.70, down 1.86% on the day, with a bearish technical signal from moving averages but oversold short-term RSI. The company maintains solid profitability with a 7.51% net margin and has beaten EPS estimates for three consecutive quarters. Revenue declined to $83.67B in 2025, though cash flow from operations improved to $9.63B. Recent news highlights Lowe's dividend growth strategy, with the quarterly payout rising to $1.25.
The outlook is mixed: strong analyst consensus (60.79% buy ratings) and a $260.88 price target suggest upside, but technical weakness and high debt levels pose risks. Earnings stability and dividend growth support long-term value, though housing market sensitivity and competitive pressures remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
